Health Care · Surgical & Medical Instruments & Apparatus · Nasdaq · CIK 1235912 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $4.95Day +1.43%Mkt cap $131M1Y −41.3%Off 52W high −56.2%Vol (1Y) 78.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 941 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest7.3% of sh out |
| Days to cover8.9d |
| 13F net flow (QoQ)−0.05% |
| Top-10 13F concentration80.1% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$59.1M |
| Earnings (TTM)-$52.7M |
| ROE−96.6% |
| Net margin−94.1% |
| ROIC−294.3% |
| Debt / equity1.26× |
| Sales growth 3Y36.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−30.3% |
| 1Y−41.3% |
| 3Y−72.1% |
| Since incept. (ann.)−15.7% |
Total return through 2026-07-28 · series begins 2022-10-18. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)78.0% |
| Ann. volatility (3Y)93.0% |
| Sharpe (1Y)−0.30 |
| Sharpe (3Y)0.05 |
| Max drawdown (1Y)−56.2% |
| Max drawdown (3Y)−85.6% |
| Beta (3Y vs SPY)1.02 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| JOHNSON & JOHNSON | 4.0M | $38M | 15.17% | +0.0% |
| NEA Management Company, LLC | 2.0M | $19M | 7.64% | +0.0% |
| BlackRock, Inc. | 1.0M | $10M | 3.87% | −3.3% |
| GSK plc | 1.0M | $10M | 3.80% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 911,310 | $9M | 3.43% | new |
| ROYAL BANK OF CANADA | 706,950 | $7M | 2.66% | +6559.3% |
| Balyasny Asset Management L.P. | 630,812 | $6M | 2.38% | −22.6% |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 572,021 | $5M | 2.16% | −9.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.50 | — | $14.8M | +19.6% |
| 2025-12-31 | 2026-02-12 | — | — | $16.0M | +4.4% |
| 2025-09-30 | 2025-11-05 | −$0.49 | — | $14.7M | +9.8% |
| 2025-06-30 | 2025-08-04 | −$0.57 | — | $13.6M | +15.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 93d) — not company-confirmed.
US 92% · DE 8%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
